0
0
Read Time:5 Minute, 27 Second
[Redding, California] — Meticulous Research®, a leading global market research and consulting firm, has unveiled its latest report on the biopharmaceutical processing equipment and consumables market, projecting significant growth driven by increasing demand for biopharmaceuticals. The report estimates the market to reach a valuation of $75.72 billion by 2031, with a compound annual growth rate (CAGR) of 9.5% from 2024 to 2031.
Rising Demand for Biopharmaceuticals Fuels Market Growth
Biopharmaceuticals, derived from living organisms using advanced biotechnological processes, have become pivotal in treating a wide spectrum of diseases. These therapies minimize treatment-related toxicity while maximizing therapeutic efficacy, making them an essential component of modern medicine. As more companies invest in biopharmaceutical research and production, the demand for specialized consumables and equipment has surged.
The growing need for innovative production solutions is also driven by technological advancements in bioprocessing equipment, enabling manufacturers to overcome production challenges and optimize efficiency. This trend is expected to propel the adoption of next-generation biopharmaceutical processing tools across the industry.
Download Sample Report Here: https://www.meticulousresearch.com/download-sample-report/cp_id=4200
Monoclonal Antibody Production: A Major Driver of Biopharmaceutical Equipment Demand
Monoclonal antibodies (mAbs), which are proteins engineered to target specific receptors or antigens on cell surfaces, have become a cornerstone in drug development and therapeutic applications. Due to their high specificity, mAbs are increasingly being used for targeted treatments, creating significant demand for biopharmaceutical processing equipment.
In 2023, the U.S. Food and Drug Administration (FDA) approved 12 therapeutic antibodies, including breakthrough mAbs like Pozelimab (VEOPOZ) and Elranatamab (Elrexfio). Several more monoclonal antibodies are currently under review by the FDA and the European Medicines Agency (EMA), poised to enter production upon approval. The rising volume of approved therapies is expected to drive demand for the equipment and consumables needed for large-scale commercial manufacturing.
Moreover, major biopharmaceutical companies such as Amgen Inc. (U.S.) and UCB (Belgium) are collaborating on groundbreaking biologics, including EVENITY, a treatment for postmenopausal osteoporosis, further signaling strong market growth.
Biopharmaceutical Processing Equipment and Consumables Market Research Summary
| Particulars | Details |
| Number of Pages | 294 |
| Format | |
| Forecast Period | 2024–2031 |
| Base Year | 2023 |
| CAGR (Value) | 9.5% |
| Market Size (Value) | USD 75.72 Billion by 2031 |
| Segments Covered | By Product Type
By Application
By End User
|
| Countries Covered | North America (U.S. and Canada), Europe (Germany, France, U.K., Italy, Spain, Switzerland, Belgium, Ireland, Denmark, and Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, and Rest of Asia-Pacific), Latin America, and Middle East & Africa |
| Key Companies | 3M Company (U.S.), Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), Agilent Technologies, Inc (U.S.), Repligen Corporation (U.S.), Sartorius AG (Germany), Merck KGaA (Germany), Eppendorf AG (Germany), and Solaris Biotechnology Srl (Italy).). |
Quick Buy: https://www.meticulousresearch.com/Checkout/87973509
Adoption of Single-Use Bioreactors Gains Momentum
Single-use bioreactors, also known as disposable bioreactors, are revolutionizing the biopharmaceutical production landscape. These systems utilize disposable bags instead of traditional stainless steel or glass vessels, offering multiple advantages such as flexibility, reduced contamination risks, and cost savings.
Biopharmaceutical companies are increasingly leveraging single-use bioreactors to streamline the production of multiple therapies within a single facility, optimizing both time and cost. The absence of cleaning-in-place (CIP) and sterilization-in-place (SIP) systems makes single-use bioreactors highly appealing, as they eliminate the need for extensive cleaning protocols and sterilization steps.
Additionally, these bioreactors are favored for their ease of use, safety, and ability to minimize batch-to-batch microbial contamination, contributing to their widespread adoption across various bioprocessing applications, including human and insect cell cultures.
Regional Insights: Europe’s Biopharmaceutical Sector Takes the Lead
Europe is expected to hold a substantial share of the biopharmaceutical processing equipment and consumables market in 2024, bolstered by the region’s thriving biopharmaceutical industry and strong government support for innovative healthcare solutions. Several companies across Europe are expanding their production capacities and operational footprints, driving the adoption of biopharmaceutical technologies throughout the region.
The European Union’s regulatory authorities are playing a crucial role in promoting biopharmaceuticals for a variety of health applications, further reinforcing Europe’s leadership position in this rapidly growing market.
Opportunities and Challenges Ahead
The biopharmaceutical processing equipment and consumables market is set for robust growth, with key opportunities emerging from the rising demand in developing economies, the ongoing shift toward Bioprocessing 4.0, and the increasing focus on personalized medicines. However, the complexity of biopharmaceutical development, coupled with the high capital investment required for production, presents significant challenges for manufacturers.
While technological advancements are helping companies overcome some production hurdles, the market’s potential could be further unlocked by addressing capital constraints and enhancing manufacturing capabilities.
Request Sample PDF Copy Here: https://www.meticulousresearch.com/request-sample-report/cp_id=4200
Conclusion
The biopharmaceutical industry is undergoing transformative growth, with increasing demand for specialized processing equipment and consumables. As companies expand their biopharmaceutical portfolios and embrace new technologies like single-use bioreactors, the market is poised for significant expansion. However, to fully capitalize on these opportunities, industry players must navigate the complexities of production and address the financial barriers associated with large-scale biopharmaceutical manufacturing.
About Meticulous Research®
Meticulous Research® is a leading provider of comprehensive market intelligence, offering actionable insights and analysis across various industries. Our reports empower businesses to make informed decisions, drive growth, and remain competitive in a rapidly evolving marketplace.
Contact:
Meticulous Market Research Pvt. Ltd.
1267 Willis St, Ste 200 Redding,
California, 96001, U.S.
USA: +1-646-781-8004
Europe : +44-203-868-8738
APAC: +91 744-7780008
Email- sales@meticulousresearch.com
Visit Our Website: https://www.meticulousresearch.com/
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
